Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

NanoSphere Health Sciences Inc (2CG) AI Stock Analysis

DE:2CG

NanoSphere Health Sciences Inc

(Frankfurt:2CG)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Narrowing Cash BurnThe lower burn rate indicates some improvement in cash discipline and could extend financing runway relative to earlier periods. However, the company remains cash-flow negative and not self-funding, so this benefit supports stabilization rather than demonstrating a durable operating model.
Negative Factors
No Revenue BaseThe absence of reported revenue indicates that the company has not established a commercial operating base in the period shown. Without recurring sales, there is limited evidence of product-market traction or internally funded growth, leaving future progress dependent on successful commercialization.

NanoSphere Health Sciences Inc (2CG) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:2CG-63.33%EWG+4.43%Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 205.50K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.8
Beta (1Y)
-10.88
Revenue Growth
―
EPS Growth
-132.51%
Country
Germany
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

NanoSphere Health Sciences Inc Business Overview & Revenue Model

Company Description

NanoSphere Health Sciences Inc. is a nano-biotechnology enterprise operating in the United States and Canada, specializing in the provision of biologically active compounds. The company's primary offering is the NanoSphere Delivery System, an innovat...

NanoSphere Health Sciences Inc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:2CG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:VXLTSE:VXL37UnderperformCAD 398.40K1.0034.52%―――
TSE:CHGXTSE:CHGX24UnderperformCAD 415.65K-0.2319.40%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:2CGTSE:WESA.XTSE:ABRTTSE:VXLTSE:CHGXFeb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:2CG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:2CGNanosphere Health Sciences0.01-0.02-63.33%
TSE:WESA.XWesana Health Holdings Inc0.010.000.00%
TSE:ABRTAlbert Labs International Corp.0.010.000.00%
TSE:VXLVaxil Bio0.10-0.07-41.18%
TSE:CHGXChitogenx Inc.0.010.000.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.